Exelixis, Inc. (NASDAQ:EXEL) Director George Poste sold 25,000 shares of the firm’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $20.50, for a total transaction of $512,500.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

George Poste also recently made the following trade(s):

  • On Friday, August 9th, George Poste sold 20,000 shares of Exelixis stock. The shares were sold at an average price of $20.60, for a total transaction of $412,000.00.

EXEL traded up $0.93 during trading on Monday, hitting $22.65. The stock had a trading volume of 3,689,809 shares, compared to its average volume of 3,238,542. The firm has a market cap of $6.04 billion, a PE ratio of 15.84 and a beta of 1.98. Exelixis, Inc. has a 12 month low of $13.42 and a 12 month high of $25.31. The company has a current ratio of 8.64, a quick ratio of 8.53 and a debt-to-equity ratio of 0.02. The company has a 50 day simple moving average of $20.89 and a 200-day simple moving average of $21.52.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Wednesday, July 31st. The biotechnology company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.23 by $0.02. The firm had revenue of $240.28 million for the quarter, compared to the consensus estimate of $226.97 million. Exelixis had a net margin of 70.52% and a return on equity of 31.31%. The business’s quarterly revenue was up 29.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.31 EPS. As a group, sell-side analysts anticipate that Exelixis, Inc. will post 0.89 earnings per share for the current fiscal year.

EXEL has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Exelixis from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a report on Tuesday, August 6th. Cowen set a $25.00 target price on shares of Exelixis and gave the stock a “buy” rating in a report on Wednesday, July 31st. ValuEngine downgraded shares of Exelixis from a “hold” rating to a “sell” rating in a report on Wednesday, July 24th. Stifel Nicolaus lifted their target price on shares of Exelixis from $22.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, August 1st. Finally, BidaskClub upgraded shares of Exelixis from a “sell” rating to a “hold” rating in a report on Friday, July 19th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $27.75.

A number of institutional investors and hedge funds have recently made changes to their positions in EXEL. Colony Group LLC bought a new stake in shares of Exelixis during the second quarter worth approximately $2,673,000. International Biotechnology Trust PLC grew its holdings in Exelixis by 82.1% during the second quarter. International Biotechnology Trust PLC now owns 443,534 shares of the biotechnology company’s stock valued at $9,483,000 after purchasing an additional 200,000 shares during the period. Orbimed Advisors LLC grew its holdings in Exelixis by 39.7% during the second quarter. Orbimed Advisors LLC now owns 3,912,900 shares of the biotechnology company’s stock valued at $83,619,000 after purchasing an additional 1,111,000 shares during the period. Ladenburg Thalmann Financial Services Inc. grew its holdings in Exelixis by 32.0% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 83,820 shares of the biotechnology company’s stock valued at $1,798,000 after purchasing an additional 20,310 shares during the period. Finally, United Services Automobile Association grew its holdings in Exelixis by 23.2% during the second quarter. United Services Automobile Association now owns 93,903 shares of the biotechnology company’s stock valued at $2,007,000 after purchasing an additional 17,703 shares during the period. Hedge funds and other institutional investors own 76.79% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Read More: What is the operating income formula?

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.